samedan logo
 
 
spacer
home > pmps > spring 2021 > the new imperative
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The New Imperative

There is growing recognition across the pharmaceutical community that air pollution is placing a considerable burden on global health. Although levels of pollution are noticeably different in established and emerging economies, it is reported that, on average, 90% of people breathe polluted air, and studies have linked this to higher than average mortality rates, with an estimated 5 million people dying annually as a result (1-2).

This alarming figure is attributable, in large part, to air pollution’s role in triggering or exacerbating respiratory-related diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and even lung cancer. Some of the world’s leading minds on pollution from academia and industry met during a roundtable to discuss the topic of air pollution and agree upon some opportunities to make a difference in a meaningful way.

One particular challenge with the subject of pollution and its impact is that there is no clear and simple solution. Because the causes are various and the effects multiple, pollution is regarded as a holistic problem, with no obvious aspects that can be translated into a business case for the development of targeted treatments. This complexity is counterbalanced by the importance of the issue at hand, and the imperative to take the first steps towards finding solutions.

In this paper we will look to better understand pollution and its impact on our respiratory system and overall health, explore the unmet medical needs and discuss several approaches to minimise and treat the effects of pollution. We will also review the steps the pharmaceutical industry can take to help alleviate the issues associated with pollution and what role device partners can play in addressing these challenges.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Gerallt Williams is Director, Scientific Affairs, Prescription Division, at Aptar Pharma. After obtaining his PhD from the University of Wales, UK, in 1985, Gerallt has held various industrial positions at Monsanto Inc, UK, Fisons Ltd, UK, Valois, France, and Inhale/Nektar Therapeutics, US. Dr Williams is now in charge of scientific affairs for the Aptar Pharma prescription division in Le Vaudreuil, France.

Dr Degenhard Marx is a Director of Scientific Affairs within the Aptar Pharma Consumer Health Care Division. Following his study of Veterinary Medicine, and the successful completion of his thesis at the University of Leipzig, Germany, in 1992, he joined the pharmaceutical industry. In 2008, he became Business Development Manager within Aptar Pharma and in 2012 he became Director of Scientific Affairs.

Julie D Suman, Registered Pharmacist, PhD is the Founder of Next Breath, an Aptar Pharma business, and serves as its President. Dr Suman holds a BS in Pharmacy from Duquesne University (1996) and a PhD in Pharmaceutical Sciences from the University of Maryland, Baltimore, US (2002). She is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr Suman is the Past-Chair of the AAPS Inhalation Technology Focus Group.
spacer
Dr Gerallt Williams
spacer
spacer
spacer
Dr Degenhard Marx
spacer
spacer
spacer
Julie D Suman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera to build state-of-the-art manufacturing facility in Poland to serve more customers and patients

Based in Szczecin, this facility extends Nemera’s manufacturing capabilities and will bring more drug delivery device solutions to patients. Following the dynamic growth of the drug delivery devices market, as a world leader, Nemera is thrilled to extend its manufacturing capabilities in Poland.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement